Mr. Todd Shapiro reports

RHELION LIFE SCIENCES SIGNS AGREEMENT WITH UNIVERSITY HEALTH NETWORK FOR RANDOMIZED CLINICAL TRIAL OF PSILOCYBIN IN PARKINSON'S DISEASE DEPRESSION

Rhelion Life Sciences Corp.'s wholly owned subsidiary, Filament Health Corp., has entered into a licence agreement with University Health Network (UHN) in Toronto for the supply of PEX010 to an investigator-initiated clinical trial titled "Evaluating the Use of Psilocybin to Treat Parkinson's Depression: A Randomized Clinical Trial" (PSI-PARK).

PSI-PARK is a randomized clinical trial evaluating psilocybin for the treatment of depression in people living with Parkinson's disease. The study is sponsored by UHN and will be conducted by the principal investigator, Dr. Joshua Rosenblat, and researchers at UHN. Filament will supply PEX010 for use in the study as the investigational drug product. Note: Filament is not the sponsor of the trial and is not responsible for its conduct.

Depression affects a substantial proportion of people living with Parkinson's disease and is among the strongest predictors of functional decline and reduced quality of life. It responds poorly to existing antidepressant treatment, and people with neurodegenerative disease have historically been excluded from psychedelic clinical research on safety grounds, leaving the therapeutic potential of psilocybin in this population largely unexamined. Depression in Parkinson's disease therefore represents a significant unmet clinical need in an area where the scientific question remains genuinely open.

PSI-PARK adds to an emerging body of clinical research in this indication. In April, 2025, results of an open-label pilot study in people with mild to moderate Parkinson's disease and mood dysfunction were published in Neuropsychopharmacology, reporting the first clinical data on psilocybin in any neurodegenerative disease. No serious adverse events were observed, and improvements in depression and anxiety measures were sustained to the final assessment. A larger randomized trial in the same indication is now under way.

PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical-grade natural psilocybin, supporting more than 80 academic and philanthropic research studies around the world. PEX010 is available in a standardized dosing range of 0.5, one, five and 25 milligrams from a single drug candidate, produced using Filament's proprietary extraction, purification and stabilization methods, giving investigators consistent composition across every dose, every study and every research site. On April 30, 2026, the company completed its previously announced acquisition of Filament Health, including its portfolio of 76 issued patents across 15 patent families and its lead drug candidate, PEX010.

About Rhelion Life Sciences Corp.

Rhelion Life Sciences is a science- and research-led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary, Filament Health, the company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate-use programs with leading institutions around the world.

We seek Safe Harbor.